Cytokeratin 5 Antibody (3E2F1): sc-81702

Cytokeratin 5 Antibody (3E2F1) is a mouse monoclonal IgG1 antibody that detects Cytokeratin 5 (CK5) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry with paraffin-embedded sections (IHCP). CK5 monoclonal antibody (3E2F1) recognizes a vital component of the cytoskeletal structure in epithelial cells, primarily found in the basal layer of stratified epithelia, where CK5 plays a crucial role in maintaining cellular integrity and resilience against mechanical stress. Anti-CK5 antibody (3E2F1) targets a protein whose location is significant in forming a robust barrier that protects underlying tissues from injury and infection. CK5 (3E2F1) monoclonal antibody identifies a protein essential for basal cell differentiation, and CK5 expression serves as a key marker in diagnosing various epithelial tumors, making anti-CK5 antibody (3E2F1) invaluable in cancer research and pathology. Mutations in the gene encoding CK5 (KRT5) can lead to severe skin disorders, such as epidermolysis bullosa, highlighting CK5′s importance in both normal physiology and disease states. Anti-CK5 antibody (3E2F1) serves as an essential tool for researchers and clinicians exploring cytokeratin roles in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 5 Antibody (3E2F1) References:

1. Cytokeratin 5/6 immunostaining in cutaneous adnexal neoplasms and metastatic adenocarcinoma.  |  Plumb, SJ., et al. 2004. Am J Dermatopathol. 26: 447-51. PMID: 15618924
2. Cytokeratin 5/6 expression in benign and malignant breast lesions.  |  Bhalla, A., et al. 2010. Indian J Pathol Microbiol. 53: 676-80. PMID: 21045391
3. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.  |  Edgecombe, A., et al. 2012. Appl Immunohistochem Mol Morphol. 20: 264-71. PMID: 22498670
4. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.  |  Inanc, M., et al. 2014. Med Oncol. 31: 801. PMID: 24326984
5. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.  |  Abdelrahman, AE., et al. 2017. Ann Diagn Pathol. 28: 43-53. PMID: 28648939
6. Utility of GATA-3 and Cytokeratin 5/6 Immunostains in Separating Condyloma Acuminatum Arising in the Urinary Tract From Non-Invasive Papillary Urothelial Carcinoma.  |  Montoya-Cerrillo, D., et al. 2022. Int J Surg Pathol. 30: 260-264. PMID: 34665053
7. Antimicrobial peptide nisin induces spherical distribution of macropinocytosis-like cytokeratin 5 and cytokeratin 17 following immediate derangement of the cell membrane.  |  Kitagawa, N. 2022. Anat Cell Biol. 55: 190-204. PMID: 34903675
8. fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions.  |  Soares, M., et al. 2022. Animals (Basel). 12: PMID: 35804497
9. TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin.  |  Almási, S., et al. 2023. Virchows Arch. 482: 861-868. PMID: 37012444
10. Altered cytokeratin 5 expression in breast lobular myoepithelial cells.  |  Li, A., et al. 2024. J Clin Pathol. 77: 536-543. PMID: 37116947

The preferred Cytokeratin 5 antibody is Cytokeratin 5 Antibody (RCK103): sc-32721.